Education
About Us
Working with TipRanks
Follow Us
Mereo Biopharma (MREO)
:MREO
MREO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.47 - $4.72
Previous CloseN/A
Volume219.93K
Average Volume (3M)1.20M
Market Cap
$311.64M
Enterprise Value$377.77M
Total Cash (Recent Filing)$56.13M
Total Debt (Recent Filing)$601.00K
Price to Earnings (P/E)―
Beta0.91
Next Earnings
Nov 18, 2025EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding159,096,880
10 Day Avg. Volume1,635,734
30 Day Avg. Volume1,202,494
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.21
Enterprise Value/Revenue241.50
Enterprise Value/Gross Profit1.10K
Enterprise Value/Ebitda-8.08
Forecast
1Y Price Target
$7.20Price Target Upside267.35% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe strong Phase 2 precedent, with significant fracture rate reduction and bone mineral density gains, combined with a less stringent statistical threshold at the final analysis, adds to the comfort in a positive outcome.
Financial StabilityMREO ended with $56.1M cash, which the company is guiding as sufficient to fund operations into 2027.
Market OpportunitySetrusumab is expected to address a significant unmet need in osteogenesis imperfecta as an active and safe treatment, corresponding to a large market opportunity.
Bears Say
Clinical Trial ChallengesThe second interim analysis of Orbit did not meet the primary endpoint of annualized fracture rate reduction at the pre-specified threshold.
Stock PerformanceMREO shares are down approximately 35% on the news.
Mereo Biopharma Group Plc News
MREO FAQ
What was Mereo Biopharma’s price range in the past 12 months?
Mereo Biopharma lowest stock price was $1.47 and its highest was $4.72 in the past 12 months.
What is Mereo Biopharma’s market cap?
Mereo Biopharma’s market cap is $311.64M.
When is Mereo Biopharma’s upcoming earnings report date?
Mereo Biopharma’s upcoming earnings report date is Nov 18, 2025 which is in 35 days.
How were Mereo Biopharma’s earnings last quarter?
Mereo Biopharma released its earnings results on Aug 12, 2025. The company reported -$0.02 earnings per share for the quarter, missing the consensus estimate of -$0.012 by -$0.008.
Is Mereo Biopharma overvalued?
According to Wall Street analysts Mereo Biopharma’s price is currently Undervalued.
Does Mereo Biopharma pay dividends?
Mereo Biopharma does not currently pay dividends.
What is Mereo Biopharma’s EPS estimate?
Mereo Biopharma’s EPS estimate is >-0.01.
How many shares outstanding does Mereo Biopharma have?
Mereo Biopharma has 159,096,880 shares outstanding.
What happened to Mereo Biopharma’s price movement after its last earnings report?
Mereo Biopharma reported an EPS of -$0.02 in its last earnings report, missing expectations of -$0.012. Following the earnings report the stock price went up 9.211%.
Which hedge fund is a major shareholder of Mereo Biopharma?
Currently, no hedge funds are holding shares in MREO
Mereo Biopharma Group Plc Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.20 (267.35% Upside)
$7.20 (267.35% Upside)
Blogger Sentiment
Bullish
MREO Sentiment 70%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Decreased
By 1.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.9%
Last 30 Days ▲ 8.0%
Last 30 Days ▲ 8.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.42%
12-Months-Change
Fundamentals
Return on Equity
-75.08%
Trailing 12-Months
Asset Growth
-34.85%
Trailing 12-Months
Company Description
Mereo Biopharma
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
MREO Stock 12 Month Forecast
Average Price Target
$7.20
▲(267.35% Upside)
Technical Analysis
Ownership Overview
1.32% Insiders
0.57% Mutual Funds
41.37% Other Institutional Investors
56.40% Public Companies and
Individual Investors